Navicixizumab Biosimilar Bispecific Antibody (DLL4 × VEGF-A) for Research

Cat No.: GMP-Bios-ab-369

Pre-Made Navicixizumab biosimilar, Bispecific mAb, Anti-DLL4;VEGFA Antibody: Anti-AOS6/delta4/hdelta2;VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Navicixizumab is an anti-DLL4/VEGF bispecific antibody that has demonstrated robust in vivo antitumor efficacy in a number of solid tumor xenografts. In the phase Ia trial of the monotherapy, 66 patients with various solid tumors were treated once every 3 weeks in 1 of 8 dose-escalation cohorts or an expansion cohort.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-ab-369-1mg 1mg
GMP-Bios-ab-369-10mg 10mg
GMP-Bios-ab-369-100mg 100mg
GMP-Bios-ab-369-xmg >100mg



Product Details

Products Name (INN Index) Pre-Made Navicixizumab biosimilar, Bispecific mAb, Anti-DLL4;VEGFA Antibody: Anti-AOS6/delta4/hdelta2;VPF/VEGF/MVCD1 therapeutic antibody
INN Name Navicixizumab
TargetDLL4;VEGFA
FormatBispecific mAb
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2015
Year Recommended2016
CompaniesOncoMed Pharmaceuticals
Conditions Approvedna
Conditions ActiveFallopian tube cancer;Ovarian cancer;Peritoneal cancer
Conditions DiscontinuedColorectal cancer;Solid tumours
Development Techna



About target - DLL4

1. Protein Leukocyte immunoglobulin-like receptor subfamily A member 4

2. Gene LILRA4

3. Organism Homo sapiens (Human)

Function
Functions coreceptor to limit the innate immune responses to viral infections; signaling occurs via FCER1G (PubMed:16735691, PubMed:19564354).
Down-regulates the production of IFNA1, IFNA2, IFNA4, IFNB1 and TNF by plasmacytoid dendritic cells that have been exposed to influenza virus or cytidine-phosphate-guanosine (CpG) dinucleotides, indicating it functions as negative regulator of TLR7 and TLR9 signaling cascades (PubMed:16735691, PubMed:19564354, PubMed:24586760).
Down-regulates interferon production in response to interaction with BST2 on HIV-1 infected cells (PubMed:26172439).
Activates a signaling cascade in complex with FCER1G that results in phosphorylation of Src family and Syk kinases and thereby triggers mobilization of intracellular Ca2+ (PubMed:16735691, PubMed:19564354).
Does not interfere with the differentiation of plasmacytoid dendritic cells into antigen-presenting cells (PubMed:24586760).